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SummaryLoss of FOXO3 transcription function, associated with human IBD and colon cancer progression, facilitates inflammatory colon cancer in mice. Transcriptome profiling of FOXO3 deficient colon and tumors revealed an immune landscape, molecular pathways, and novel transcripts similarly dysregulated in IBD and colon cancer.

Colon cancer, the second leading cause of cancer-related death in the United States, is driven by alterations in the tissue microenvironment caused by obesity, imbalances in the microbiome, and inflammation.[@bib1], [@bib2], [@bib3] Local, chronic inflammation of the colon, as observed in inflammatory bowel disease (IBD), is associated with increased risk of cancer development and progression.[@bib4], [@bib5] The inflammatory microenvironment initiates and fosters cancer progression as evident by its ability to stimulate transformed cell proliferation, survival, angiogenesis, metastasis, and resistance to chemotherapy.[@bib1] Dynamic communication among cancer cells and the inflammatory microenvironment favors immune cell infiltration and the release of cytokines and growth mediators, both facilitators of cancer progression.[@bib3] Furthermore, inflammation generated reactive nitrogen and oxidative species have been shown to mediate genetic instability in cancer cells.[@bib1] In the colon, inflammation-mediated genetic microsatellite instability (MSI) favors an increased mutation rate leading to cancer progression.[@bib1], [@bib6] However, the nature of the immune cell types, inflammatory mediators, and transcriptional programs that drive inflammation-mediated colon cancer are neither fully examined nor understood.

Transcription factor FOXO3, a member of the forkhead box O (FOXO) family, plays critical roles in diverse cellular functions including proliferation, apoptosis, and metabolism.[@bib7], [@bib8] In immune cells, FOXO3 activity is critical for maintenance of immune progenitor cell homeostasis,[@bib9], [@bib10] and its deficiency in B and T cells leads to their enhanced activity during infection.[@bib11] In patients with inflammatory diseases such as rheumatoid arthritis and IBD, genome-wide association studies have shown that individuals with a single nucleotide polymorphism (SNP) in the FOXO3 gene locus leading to lowered FOXO3 expression have a more aggressive disease course.[@bib12] Moreover, in human colon cancer tissues loss of FOXO3 transcription activity is associated with tumor growth.[@bib13] Previously, we demonstrated that mice deficient in FOXO3 have increased susceptibility to colonic inflammation and elevated rates of cell proliferation.[@bib14], [@bib15] Thus, we hypothesized that FOXO3's immunosuppressive and tumor-suppressive functions might intersect to drive inflammation-mediated colon cancer. Here, we aimed to determine loss of FOXO3-dependent changes in the immune landscape, molecular pathways, and downstream transcripts involved in disease pathobiology.

We demonstrated that in a mouse model of inflammation-mediated colon cancer FOXO3 deficiency led to increased tumor burden, an altered immune cell landscape, activated molecular pathways, and transcriptional programs associated with inflammation and tumor growth. Our analysis identified FOXO3-dependent transcripts that could potentially serve as biomarkers and prospective new targets for treatment.

Materials and Methods {#sec1}
=====================

Animals {#sec1.1}
-------

Wild-type (WT) and FOXO3 knockout (FOXO3 KO) mice on a C57BL/6 genetic background[@bib11] were housed at the Tulane University School of Medicine, a pathogen-free facility in static, microisolator caging. Homozygous littermates were offspring of heterozygous breeders and genotyped as described by Lin et al.[@bib11] All experiments were completed according to guidelines and procedures determined by the Tulane Institutional Animal Care and Use Committee.

Azoxymethane and Dextran Sulfate Sodium Treatment {#sec1.2}
-------------------------------------------------

Mice, 6--8 weeks old, were injected intraperitoneally with a single dose (10 mg/kg) of azoxymethane (AOM) (Sigma-Aldrich, St Louis, MO; A5486) and subsequently administered 3 cycles of 2.5% dextran sulfate sodium (DSS) (MP Biomedicals, Santa Ana, CA; 160110) in drinking water for 5 days with 3-week intervals between each treatment regimen.[@bib16] After 8 weeks of recovery, mice were killed, and colonic tissues were collected for analysis. Tumor counts and measurements were conducted in a blinded fashion.

Cell Culture and Generation of Short Hairpin RNA Stable Cell Lines {#sec1.3}
------------------------------------------------------------------

Human colon cancer HCT116 cells (ATCC) were grown in complete McCoy's 5A medium (Corning, Corning, NY; 10050CV) supplemented with 10% fetal bovine serum (Gibco Laboratories, Gaithersburg, MD; A3160602). For generating stable short hairpin RNA (shRNA) knockdown cell lines, FOXO3-specific shRNA (shFOXO3) and control shRNA were cloned into the TET-ON all in one LT3GEPIR vector[@bib17] by using the following nucleotide shRNA guide sequences: 5′-CATGTTCAATGGGAGCTTGGA-3′ (shFOXO3), 5′-TAGATAAGCATTATAATTCCTA-3′ (shCon). Sequence verified plasmids were transfected into HCT116 cells by using lipofectamine 3000 according to manufacturer's instructions (Invitrogen, Carlsbad, CA; L3000001). Stable cell lines were generated from single cells by using puromycin selection (250 ng/mL; Sigma-Aldrich; P8833), and doxycycline-inducible (2 μg/mL; Sigma-Aldrich; D9891) knockdown of FOXO3 was validated by quantitative polymerase chain reaction (qPCR) and immunoblot.

Small Interfering RNA {#sec1.4}
---------------------

Human colon cancer HCT116 cells were transfected with integrin subunit alpha 2 (ITGA2) specific pooled small interfering RNA (Sigma-Aldrich; EHU040531) or equal amounts of negative-control scramble oligonucleotides using lipofectamine 3000 according to manufacturer's instructions (Invitrogen; L3000001). Efficiency of the knockdown was validated by qPCR and immunoblot.

Protein Extraction and Immunoblotting {#sec1.5}
-------------------------------------

Experimental cells were used for protein extraction, and immunoblot was performed as described previously.[@bib14], [@bib18] The following specific antibodies against proteins were used: FOXO3 (Cell Signaling Technology, Danvers, MA; cat 2497, lot 8), ADAM metallopeptidase with thrombospondin type 1 motif 12 (ADAMTS12) (Abcam, Cambridge, United Kingdom; cat 203012, lot GR2390174; Thermo Scientific, Waltham, MA; cat PA568084, lot SK2479822E), ITGA2 (Abcam; cat 133557, lot GR19622312), ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5 (ST8SIA5) (Abcam; cat 184777, lot GR2231323), and β-actin (Cell Signaling Technology; cat 3700, lot 8). Proteins were visualized with IRDye-conjugated secondary antibodies (LI-COR Biotechnology, Lincoln, NE; goat anti-mouse, cat 92532210, lot C6072602; goat anti-rabbit, cat 92568071, lot 92632210) using the Odyssey infrared imaging system (LI-COR Biotechnology).

Cell Proliferation Assays {#sec1.6}
-------------------------

Human colon cancer HCT116 cells were plated on 96-well plates at a density of 5000 cells per well. After 72 hours, a portion of cell medium was removed, and MTS solution (Promega, Madison, WI; M3001) was added for 1 hour and incubated at 37°C. MTS-converted formazan product was detected in cell medium solution at 490 nm by using a Microplate Reader FLUOstar Optima (BMG Labtech, Ortenberg, Germany). Cell proliferation was calculated as a percentage of the absorbance relative to untreated control cells.

RNA Isolation and cDNA Synthesis {#sec1.7}
--------------------------------

Human colon cancer cells and mouse tissues (colon and tumors) were used for isolation of total RNA by using the miRNeasy kit (Qiagen, Hilden, Germany; 217004) according to manufacturer's instructions. RNA quality was determined by an Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA), and samples with RNA integrity numbers (RIN) \>7 were used. For qPCR, RNA treated with DNase was reverse transcribed to cDNA with oligo-dT12-18 primers of the SuperScript First-Strand Synthesis System (Invitrogen; 11904018) according to the manufacturer's protocol.

Quantitative Polymerase Chain Reaction {#sec1.8}
--------------------------------------

The cDNA generated from mouse tissues and human colon cancer cells was used for qPCR as previously described.[@bib19], [@bib20] The following primers (Thermo Fisher Scientific) were used for amplification of human and mouse cDNA: Itga2 (human: hItga2-FOR 5′-GGTGCTCCTCGGGCAAATTA-3′, hItga2-REV 5′-GAGCCAATCTGGTCACCTCG-3′; mouse: mItga2-FOR 5′-TGGTAGTTGTGACCGATGGC-3′; mItga2-REV 5′-ACCCAAGAACTGCTATGCCG-3′), Adamts12 (mAdamts12-FOR 5′-CTGCCAAGGACTGACTGGATT-3′, mAdamts12-REV 5′-GTAGGACCCTTCCTCGGTCA-3′), St8sia5 (mSt8sia5-FOR 5′-CTTGTCCAGGTGCTGCAATG-3′; mSt8sia5-REV 5′-AGGGCATTTCCTTGGGAAACA-3′), Tlr4 (mTlr4-FOR 5′-AATCCCTGCATAGAGGTAGTTCC-3′, mTlr4-REV 5′-ATCCAGCCACTGAAGTTCTGA-3′), FOXO3 (hFoxo3-FOR 5′-TGGTTTGAACGTGGGGAACT-3′, hFoxo3-REV 5′-GTGTCAGTTTGAGGGTCTGCT-3′). To determine the relative levels of mRNA the comparative Ct method was used with Hprt-1 as a housekeeping control. The C1000 Thermal Cycler system (Bio-Rad, Hercules, CA) and iQ SYBR Green DNA double-strand binding dye (iQ SYBR Green Supermix; Bio-Rad; 1708885) were used to quantify cDNA. As expected, PCR amplification was unaffected in mouse colonic tumors because of ample time between the last DSS treatment and RNA extraction.[@bib21]

RNA Sequencing and Differential Expression Testing {#sec1.9}
--------------------------------------------------

RNA sequencing (RNAseq) and differential expression testing were accomplished as described previously.[@bib19], [@bib20] Specifically, RNAseq and library preparation was completed by University of Wisconsin Biotechnology Facility (<http://www.biotech.wisc.edu/services/dnaseq>). The mRNA was enriched via poly-A selection (1 μg input per sample), and the Illumina Truseq Stranded mRNA preparation kit was used for library preparation (Illumina Inc, San Diego, CA). After cDNA synthesis, indexing adapters were ligated to ends of cDNA, and PCR enrichment of DNA fragments with adapters was performed. Library quality, profile, and size were validated by using an Agilent DNA 1000 Chip (Agilent Technologies). One hundred base-pair strand-specific RNAseq was performed on validated samples by using Illuming HiSeq 2500 technology (Illumina Inc). Bioinformatics analyses of raw RNAseq data were performed in the Tulane Cancer Center Next Generation Sequence Analysis core ([www.tulane.edu/som/cancer/research/core-facilities/cancer-crusaders](http://www.tulane.edu/som/cancer/research/core-facilities/cancer-crusaders){#intref0015}). RNAseq reads were mapped to the mouse reference haploid genome sequence (Genome Reference Consortium murine genome build 38, GRCm38). Quantification of transcript expression was accomplished by using the software package RSEM (v1.2.25). Subsequent identification of differentially expressed (DE) transcripts at the whole gene level between biological conditions was performed by using EBseq and attained with a false discovery rate (FDR) of 0.05. Sequencing data along with the study design have been submitted in NCBI's Sequence Read Archive and are available under study accession number SRP158292.

Transcriptome and Pathway Analysis {#sec1.10}
----------------------------------

Networks, functional analysis, and interpretation of RNAseq data were performed by using Ingenuity Pathway Analysis (IPA) (Qiagen Inc). Transcripts entered into IPA met an expression threshold of \>\|1.5\|-fold change with respect to control and an FDR \<0.05. Transcriptional signatures from our samples were compared against available gene expression data from mouse colon with inflammation or dysplasia as well as human IBD and colon cancer samples using NCBI's GEO2R after adjustment with Benjamini and Hochberg testing (*P* \< .05).[@bib22] In addition, our transcriptional signatures were compared against transcriptomes from human colon cancer tissue (The Cancer Genome Atlas \[TCGA\]) by using Firebrowse.[@bib23]

cBioPortal for Cancer Genomics {#sec1.11}
------------------------------

Investigation of transcript dysregulation in human colon cancer samples was analyzed by using the cBioPortal for Human Cancer Genomics[@bib24], [@bib25] ([www.cbioportal.org](http://www.cbioportal.org){#intref0020}). Selected genes in human colorectal adenocarcinoma patient samples (TCGA COAD) were analyzed by using a z-score threshold of ±2 for RNAseq analyses for all tumors as quantified by RSEM (RNAseq by Expectation Maximization)[@bib26]; Case Set: All Tumors (631 patients/636 samples)).

Cell-type Identification by Estimating Relative Subsets of RNA Transcripts {#sec1.12}
--------------------------------------------------------------------------

To identify the immune cell landscape in a mixed colonic tissue sample, the computational cell-type identification by estimating relative subsets of RNA transcripts (CIBERSORT) method was applied to RNAseq data.[@bib27] Mixture files were created by using transcripts per million (TPM) from RNAseq samples according to the CIBERSORT formatting requirements (<http://cibersort.stanford.edu>). For mouse immune and colonic cells, a custom gene signature, reference, and phenotype file were created in accordance with CIBERSORT format specifications using the following RNAseq run accession numbers: B cells (SRR1976588, SRR1976593, SRR3932662, SRR3932664), CD4 T cells (SRR1976591, SRR3932665), CD8 T cells (SRR3001784, SRR3001786, SRR3001782), macrophages (SRR1976597, SRR3932663, SRR2927689), neutrophils (SRR1177062, SRR1177063, SRR3932667, SRR1976571), natural killer (NK) cells (SRR1976589, SRR3932669, SRR1976596, SRR3932670), and colonocytes (SRR3189717 \[ATCC CMT-93 cells\], SRR3189714 \[1638NT1 cells\]). Only those values meeting a significance threshold of *P* \<.05 were included in analysis.

Tumor Immune Estimation Resource {#sec1.13}
--------------------------------

Tumor immune estimation resource (TIMER) was used to assess mRNA expression in human cancer relative to normal matched tissue (RNAseq RSEM, TCGA)[@bib28] (<https://cistrome.shinyapps.io/timer/>).

Gene Set Enrichment Analysis {#sec1.14}
----------------------------

Gene set enrichment analysis (GSEA) software and the Molecular Signature Database were used to determine activation of transcription factor targets from RNAseq data.[@bib29]

Histologic Analysis {#sec1.15}
-------------------

Mouse tissue processing and immunohistostaining were performed by the Pathology Core Laboratory at Tulane University Health Sciences Center (<http://medicine.tulane.edu/departments/pathologylaboratorymedicine/research/histology-laboratory>) as described previously.[@bib19], [@bib20] Heat-induced epitope retrieval was performed on tissue sections by using Rodent Decloaker solution (BioCare Medical, Concord, CA; RD913) and cooked in an oster steamer for 40 minutes. Sections were blocked by using Rodent Block M (BioCare Medical; RBM961), followed by incubation with the following antibodies: ADAMTS12 (Abcam; cat 203012, lot GR2390174), ITGA2 (Abcam; cat 133557, lot GR19622312), ST8SIA5 (Abcam; cat 184777, lot GR2231323), and Ki67 (1:100, 45 minutes; BioCare Medical; CRM325). After washing, tissue sections were incubated with Rabbit-on-Rodent HRP-Polymer secondary (BioCare Medical; RMR622); sections were then washed and treated with Betazoid DAB chromogen (Biocare Medical; BDB2004), followed by counterstaining with Cat hematoxylin (Biocare Medical; CATHEM). Slides were dried in the oven, placed in xylene, and coverslipped (Acrymount; StatLab, McKinney, TX; SL804). Images were obtained by using the slide scanner Aperio CS2 (Leica, Wetzlar, Germany) and Image Scope software.

Statistical Analysis {#sec1.16}
--------------------

All data are means ± standard deviation for a series of experiments. Statistical analysis was performed by Student unpaired *t* test or one-way analysis of variance and Student-Newman-Keuls post-test by using Graph Pad Instat 3 software (Graphpad Software, San Diego, CA). A *P* value \<.05 was considered significant.

Results {#sec2}
=======

In Mouse Colon, Forkhead Box O3 Deficiency Leads to Increased Tumor Burden and Activates Pathways Associated With Inflammation and Cancer {#sec2.1}
-----------------------------------------------------------------------------------------------------------------------------------------

Because reduced FOXO3 transcription function has been linked to severity of human IBD and colon cancer pathobiology,[@bib12], [@bib13] we assessed how loss of its activity might contribute to inflammation-mediated colon tumor progression. Initially, analysis of transcriptomes from patients with IBD (microarray) and colon cancer tissues (microarray and RNAseq) revealed decreased FOXO3 expression across both pathologies ([Figure 1](#fig1){ref-type="fig"}*A* and *B*). Compared with matched normal tissue, FOXO3 transcript levels were also decreased in approximately 60% of other cancers (TCGA) ([Figure 1](#fig1){ref-type="fig"}*B*). In addition, reduced FOXO3 in human colon cancer was linked to poor patient survival as assessed by KM estimate ([Figure 1](#fig1){ref-type="fig"}*C*), which was further supported by pan-cancer meta-z analysis demonstrating increased FOXO3 expression as a favorable prognostic indicator in cancer survival (Stanford, prediction of clinical outcomes from genomic profiles \[PRECOG\]) ([Figure 1](#fig1){ref-type="fig"}*D*). Last, we determined in human colon cancer tissues (TCGA) whether low FOXO3 expression was associated with increased PI3K activity, which is known to negatively regulate FOXO3[@bib30] and favor cancer progression.[@bib31] In patients with the lowest FOXO3 transcript levels, 3 of 10 had PI3K activating mutations (UCSC, XENA) ([Figure 1](#fig1){ref-type="fig"}*E*), suggesting that in human colon cancer loss of FOXO3-mediated progression could be either PI3K-dependent or -independent. Together, these findings demonstrate that in human IBD and colon cancer, FOXO3 expression is reduced, in part, independently of upstream PI3K and associated with reduced patient survival.Figure 1**In human IBD and cancer, FOXO3 mRNA levels are reduced and associated with poor survival and partial PI3K activating mutations.** (*A*) In human IBD tissue samples, relative expression (microarray) of FOXO3 transcript was significantly reduced compared with normal matched control tissue (GSE4183, n = 23; Affymetrix probe ID: 204131_s\_at; \**P* \< .05, IBD compared with normal colon, Student *t* test). (*B*) mRNA expression (RNAseq, RSEM) of FOXO3 across TCGA cohorts (TIMER, <https://cistrome.shinyapps.io/timer/>). (*C*) Representative Kaplan-Meier survival plot demonstrating decreased FOXO3 mRNA expression is associated with reduced colon cancer patient survival (GSE16125, n = 32; <https://precog.stanford.edu/index.php>). (*D*) PRECOG meta-z analysis indicating increased FOXO3 expression as prognostic for favorable overall cancer survival (*P* \< .05, <https://precog.stanford.edu/index.php>). (*E*) In human colon cancer (TCGA), the 10 patients expressing the lowest FOXO3 mRNA (compared with average FOXO3 level in tumor) (RNAseq, HTseq) and their 3 (p.H1047R, p.H1048R, p.R88Q) corresponding PI3K activating mutations (MuTect2 Variant Browser) (UCSC Xena Genome Browser, <http://xena.ucsc.edu>).

By using KO mice, we assessed the loss of FOXO3-dependent transcriptional consequences that could facilitate inflammation-mediated cancer progression. In the AOM/DSS model, approximately one-third of FOXO3 KO mice displayed rectal prolapse; nevertheless, survival rates between WT and KO mice did not differ during the time of the experiment. Macroscopic examination of colon revealed that FOXO3 KO mice had a greater tumor incidence (2-fold) and size (\>3 mm), leading to a significantly increased tumor burden (3-fold) compared with WT ([Figure 2](#fig2){ref-type="fig"}*A* and *B*). Microscopic assessment of tumors (H&E stained) for penetration of surrounding lamina propria or spreading to lymph nodes did not show differences between WT and FOXO3 KO, suggesting that in this model and for the duration of the experiment, cancer invasion and metastasis appear to be independent of FOXO3 deficiency. Next, RNAseq analysis showed in FOXO3 KO colon a significant number of DE transcripts were also shared with tumors (WT and FOXO3 KO) ([Figure 2](#fig2){ref-type="fig"}*C*). IPA of these DE transcripts indicated altered biological functions pertaining to tumor growth including increased cell migration, proliferation, angiogenesis, inflammation, cancer, and decreased apoptosis ([Figure 2](#fig2){ref-type="fig"}*D*). Moreover, the FOXO3 KO transcriptional signature displayed strong similarities with inflammatory and dysplastic transcriptomes of mouse colon (GSE31106) ([Figure 2](#fig2){ref-type="fig"}*E*), suggesting its functional deficiency might support both processes. Also, we found in FOXO3 KO colon that dysregulated pathways substantially overlapped with those altered in human IBD and colon cancer (GSE4183) ([Figure 3](#fig3){ref-type="fig"}). Particularly in KO colon and AOM/DSS tumors, IPA revealed gene expression was similar to transcriptomes from human colon cancers with MSI, characterized by an inflammatory tumor microenvironment (TCGA) ([Figure 3](#fig3){ref-type="fig"}*B*). These findings demonstrate that in mouse colonic tissue, FOXO3 deficiency increases tumor burden and promotes transcriptional changes similar to those occurring in human IBD and colon cancer, especially tumors with inflammatory MSI features.Figure 2**In mouse colon FOXO3 deficiency increases colonic tumor burden and activation of inflammatory and tumorigenic transcriptional programs.** (*A* and *B*) Gross histology of WT and FOXO3 KO colonic tumors in the AOM/DSS mouse model. Colonic tumor incidence, size, and tumor burden were determined between WT and FOXO3 KO (n = 8 per experimental group, representative graph from 2 independent experiments; \**P* \< .05 compared with WT, Student *t* test). (*C*) Venn diagrams depict the number of transcripts commonly or uniquely expressed in mouse FOXO3 KO colon and tumors (WT or KO in AOM/DSS model) relative to WT (n = 3 per experimental group, FDR \< 0.05, EBseq). (*D*) Disease and function analysis of colonic FOXO3 KO transcriptome revealed association with inflammatory and cancer pathobiology (n = 3 per experimental group, FDR \< 0.05, IPA). (*E*) Top canonical pathways activated in mouse FOXO3 KO colon (n = 6) compared with both mouse inflamed and dysplastic colonic tissue (GSE31106, n = 15) (FDR \< 0.05, IPA).Figure 3**Loss of FOXO3 leads to altered transcript expression similarly observed in human intestinal inflammation and colon cancer.** (*A*) Canonical pathway analysis revealed high degree of transcriptional similarity between mouse FOXO3 KO colon (n = 6) and human IBD (GSE4183, n = 23 patient samples) (FDR \< 0.05, IPA). (*B*) Pathway analysis revealed that transcriptional signatures from mouse FOXO3 KO colon and AOM/DSS tumors shared high degree of similarity with human colon cancer, especially those with MSI (TCGA) (n = 3 per experimental group, FDR \< 0.05, IPA).

In Mouse Colon, Forkhead Box O3 Deficiency Leads to an Altered Immune Cell Landscape Similar to Inflammatory Tumors {#sec2.2}
-------------------------------------------------------------------------------------------------------------------

On the basis of the above findings and because loss of FOXO3 function is critical in mediating inflammatory and proliferative responses in both colonic and immune cells,[@bib9], [@bib14], [@bib15] we applied CIBERSORT[@bib27] to assess the relative abundance of immune cell types in experimental tissues. This program uses transcriptional signatures of distinct immune cell types to assess their presence in a mixed cell tissue by using RNAseq data.[@bib27] Compared with WT mice, FOXO3 KO colon showed significantly increased levels of macrophages (2-fold), neutrophils (3-fold), and reduced NK cells ([Figure 4](#fig4){ref-type="fig"}*A*). Also, although both B cells and T cells (CD4 and CD8) were elevated in FOXO3 KO colon, only increases in B cells (3-fold) reached statistical significance ([Figure 4](#fig4){ref-type="fig"}*B*). This immune profile, similarly described in human inflammatory colon cancer,[@bib3], [@bib32] was also seen in mouse AOM/DSS tumors (data not shown). Moreover, these findings were further supported by analysis of upstream pathways (IPA), which identified increased expression and activation of receptors and cytokines specific for the presence of macrophages (interleukin 1A, interleukin 1B) ([Figure 4](#fig4){ref-type="fig"}*C*), neutrophils (interleukin 8) ([Figure 2](#fig2){ref-type="fig"}*E*), B cells (receptor signaling) ([Figure 2](#fig2){ref-type="fig"}*E*), and T cells (interleukin 13, interleukin 17A) ([Figure 4](#fig4){ref-type="fig"}*C*). These data show that in colon and AOM/DSS tumors FOXO3 deficiency leads to an altered immune cell landscape and inflammatory microenvironment that could potentially support cancer progression.Figure 4**FOXO3 deficiency promotes infiltration of immune cells in mouse colon and tumor microenvironment.** (*A* and *B*) CIBERSORT relative abundances of select immune cell infiltrate in FOXO3 KO colon relative to WT (fold-change) (n = 3 per experimental group; \**P* \< .05 compared with WT, analysis of variance and Student-Newman-Keuls post-test). (*C*) IPA upstream regulator analysis of FOXO3 KO colon and tumor (WT and KO) transcriptomes (n = 3 per experimental group, FDR \< 0.05, IPA).

In Mouse Colon, Forkhead Box O3 Deficiency Activates Transcriptional Programs Associated With Inflammation, Tumorigenesis, and Bacterial Signaling {#sec2.3}
--------------------------------------------------------------------------------------------------------------------------------------------------

Next, we determined loss of FOXO3-dependent transcripts that may influence inflammation and cancer. Initially, GSEA recognized a prevalent number of FOXO3 DE transcripts as being regulated by inflammatory nuclear factor kappa B (NFκB) and tumorigenic cMyc transcription factors ([Figure 5](#fig5){ref-type="fig"}*A*). Moreover, among FOXO3 KO DE transcripts that were shared with AOM/DSS tumors ([Figure 2](#fig2){ref-type="fig"}*C*), we selected 50 novel transcripts ([Table 1](#tbl1){ref-type="table"}) that could play a potential role in colon cancer. IPA also demonstrated numerous elevated DE transcripts with biological roles in inflammation and cancer progression ([Figure 5](#fig5){ref-type="fig"}*B*) including S100A8, Wnt ligands, and several matrix metalloproteinases (MMPs).[@bib33], [@bib34], [@bib35] Furthermore, the transcriptome of FOXO3 KO colon displayed activated signals specific for bacterial factor(s) recognition including Toll-like receptors TLR4, TLR7, TLR8, and their downstream transducer MYD88 ([Figures 4](#fig4){ref-type="fig"}*C* and 5*B*). In particular, significant up-regulation of TLR4 expression (2.5-fold) was validated by qPCR in FOXO3 KO colon ([Figure 5](#fig5){ref-type="fig"}*C*). Several of these TLRs, expressed in colonic cells and antigen presenting cells, are associated with increased susceptibility to developing intestinal inflammation and cancer.[@bib36], [@bib37] These findings identify loss of FOXO3-dependent transcripts that have established and potential roles in inflammation and tumor growth.Figure 5**In mouse colon FOXO3 deficiency leads to activation of transcriptional programs associated with inflammation, tumorigenesis, and bacterial signaling.** (*A*) GSEA of FOXO3 KO colon transcriptome revealed activation of inflammatory and tumorigenic transcriptional motifs (n = 6, \**P* \< .05). (*B*) Heatmap profiling revealed transcripts significantly elevated in FOXO3 KO colon and tumors (WT and KO) from inflammatory and cancer signaling (n = 3 per experimental group, FDR \< 0.05, IPA). (*C*) Total RNA was extracted from WT or FOXO3 KO colon, and TLR4 mRNA levels were quantified by using qPCR (n = 4 per group from 2 independent experiments; \**P* \< .05 compared with WT colon, Student *t* test).Table 1DE Transcripts in FOXO3 KO Colon Similarly Up- and Down-Regulated in Tumors (AOM/DSS)GeneGene nameColon FOXO3 KOTumor (AOM/DSS)SGSM3Small G protein signaling modulator 3595.07891.142FAM103A1Family with sequence similarity 103, member A1565.122152.628ZBED6Zinc finger, BED type containing 6106.97361.437MCPT4Mast cell protease 441.72319.823CFDComplement factor D33.037.816ADIPOQAdiponectin, C1Q and collagen domain30.55910.799LEPLeptin25.85316.14CPA3Carboxypeptidase A3, mast cell25.0898.962ARFIP1ADP ribosylation factor interacting protein 120.4793.18S100A8[a](#tbl1fna){ref-type="table-fn"}S100 calcium binding protein A815.034792.785AMD1S-adenosylmethionine decarboxylase 114.952.282RBM12RNA binding protein 1212.77311.412MOAP1Modulator of apoptosis 112.3994.448CHSY3Chondroitin sulfate synthase 310.1474.858KLF12Kruppel like factor 127.8026.82WNT16Wnt family member 166.81437.196UPRTUracil phosphoribosyltransferase6.1742.941LCORLigand dependent nuclear receptor Corepressor6.0893.089SYNE3Spectrin repeat containing, nuclear envelope family member 35.6911.515PAPLNPapilin, proteoglycan-like sulfated glycoprotein5.623.152CBLCbl proto-oncogene5.5822.108LMBRD2LMBR1 domain containing 25.4792.988LNPEPLeucyl/cystinyl aminopeptidase5.4682.236NT5C1A5\'-nucleotidase, cytosolic IA5.1943.413ATP7AATPase, copper transporting alpha5.0983.102CCDC85CCoiled-coil domain containing 85C4.922.431PCOLCE2Procollagen C-endopeptidase enhancer 24.8461.806SLFN5Schlafen 54.7633.99SAMD12Sterile alpha motif domain containing 124.6475.439ITGA2Integrin alpha 24.35620.059EXPH5Exophilin 54.3482.457PM20D2Peptidase M20 domain containing 24.1056.56PTAR1Protein prenyltransferase alpha subunit repeat containing 14.0062.109VPS13CVacuolar protein sorting 13C41.736ADAMTS12ADAM metallopeptidase with thrombospondin type 1 motif 123.92716.032TCHHTrichohyalin3.8975.262XKR4XK related 43.8953.658MIA2Melanoma inhibitory activity 23.8472.227PDPRPyruvate dehydrogenase phosphatase regulatory subunit3.7841.999PCDHGC3Protocadherin gamma subfamily C, 33.7713.844IGFBP3[a](#tbl1fna){ref-type="table-fn"}Insulin-like growth factor binding protein 33.71110.152STON2Stonin 23.641.98ADAMTS3ADAM metallopeptidase with thrombospondin type 1 motif 33.5742.979ARSBArylsulfatase B3.5681.626TNKSTankyrase3.5022.947SERPINA3Serpin family A member 33.487.076SLC25A30Solute carrier family 25, member 303.4364.609SNX29Sorting nexin 293.3561.737WDFY2WD repeat and FYVE domain containing 23.3083.602LPAR5Lysophosphatidic acid receptor 53.2952.073LENEPLens epithelial protein--85.425--69.786USP9YUbiquitin specific peptidase 9, y-linked--42.229--22.166DDX54DEAD box polypeptide 54--21.688--2.797UGT1A4UDP glucuronosyltransferase 1 family, polypeptide A4--21.403--14.754LIPFLipase F--9.735--5.841RPGRIP1Retinitis pigmentosa GTPase regulator Interacting protein 1--5.034--3.058RPL41Ribosomal protein L41--4.189--2.691CES3Carboxylesterase 3--3.743--6.789RAB33ARAB33A, member RAS oncogene family--3.669--4.316RGS1Regulator of G-protein signaling 1--3.665--5.723NTAN1N-terminal Asn amidase--3.566--2.115UGT1A1UDP glucuronosyltransferase 1 family, polypeptide A1--3.531--2.425UGT2B17UDP glucuronosyltransferase family 2, member B17--3.505--3.248MFSD9Major facilitator superfamily domain containing 9--3.397--2.942SPDYASpeedy/RINGO cell cycle regulator family, member A--3.128--1.815SLC17A1Solute carrier family 17, member 1--2.86--2.822CFAP52Cilia and flagella associated protein 52--2.763--1.652DPPA5Developmental pluripotency associated 5--2.698--3.306NR1I3Nuclear receptor subfamily 1 group I member 3--2.674--6.541SERPINC1Serpin family C member 1--2.57--1.717CDACytidine deaminase--2.547--1.518TATTyrosine aminotransferase--2.402--3.944NLRP9NLR family pyrin domain containing 9--2.339--5.906GDPD2Glycerophosphodiester phosphodiesterase domain containing 2--2.28--2.539NEK3NIMA related kinase 3--2.235--3.583CCDC62Coiled-coil domain containing 62--2.234--3.062ST8SIA5ST8 aspha-N-acetyl-neuraminide alpha-2,8-sialytransferase 5--2.232--6.472CHKBCholine kinase beta--2.219--2.888IL5RAInterleukin 5 receptor subunit alpha--2.218--2.015RPL10ARibosomal protein L10A--2.2--1.514RPS13Ribosomal protein s13--2.191--1.329PIGHPhosphatidylinositol glycan anchor biosynthesis, class H--2.159--2.072LINGO4Leucine rich repeat and lg domain containing 4--2.159--5.562CCDC152Coiled-coil domain containing 152--2.131--3.069RSRP1Arginine/serine rich protein 1--2.13--1.756ALS2CLAls2 C-terminal like--2.081--1.219B3GAT2Beta-1,3-glucuronyltransferase 2--2.074--1.656Aph1cAph1 homolog, gamma secretase subunit--2.059--3.541CYP2C44Cytochrome family 2, subfamily c, polypeptide 23--2.049--5.493GALGalanin--2.045--1.863SUN3Sad1 and UNC84 domain containing 3--2.044--2.582FTH1Ferritin heavy polypeptide 1--2.033--1.886PLSCR4Phospholipid scramblase 4--2.028--3.39TCF7L2Transcription factor 7 like 2--2.015--2.63PNPPurine-nucleoside phosphorylase--2.008--2.019RHBDL1Rhomboid like 1--1.997--2.056ARGLU1Arginine and glutamate rich 1--1.991--1.564GSDMCGasdermin C--1.987--5.246OOEPOocyte expressed protein--1.981--5.338AQP8Aquaporin 8--1.967--9.629[^1]

Altered Expression of Novel Integrin Subunit Alpha 2, ADAM Metallopeptidase With Thrombospondin Type 1 Motif 12, and ST8 Alpha-N-Acetyl-Neuraminide Alpha-2,8-Sialyltransferase 5 Transcripts in Mouse and Human Colon and Tumors {#sec2.4}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Because our bioinformatics revealed FOXO3 deficiency altered transcripts that were also dysregulated in tumors, we used molecular approaches to validate expression of select DE transcripts in FOXO3 KO colon and tumors (WT and KO). Among transcripts positively or negatively dependent on FOXO3, we selected those genes (significantly DE) with diverse functions and select abundances in colonic and non-colonic cells. Specifically, we validated ITGA2, a membrane and intracellular integrin family member highly expressed in the colon,[@bib38] ADAMTS12, an extracellular and intracellular metallopeptidase family with expression in colonic and non-colonic cells,[@bib39] and ST8SIA5, a sialyltransferase involved in ganglioside synthesis, with low basal expression in the colon and possible localization to the Golgi.[@bib40] Quantitative PCR and immunohistostaining showed significantly increased expression of ITGA2 and ADAMTS12 as well as decreased ST8SIA5 in FOXO3 KO colon and tumors relative to WT ([Figure 6](#fig6){ref-type="fig"}) confirming RNAseq data. In mouse WT colon, ITGA2 protein was present in colonic cells, mostly localized in the membrane of proliferative cells of the crypt, whereas in KO colon and tumors, its overall levels were considerably augmented. Also, in mouse WT colon, ADAMTS12 protein was localized in colonic cells (intracellular and membrane) along the crypt, whereas in FOXO3 KO colon and tumors, it was elevated in colonic but more noticeably in non-colonic cells. ST8SIA5 was present at lower levels in colonic cells, more so in upper parts of crypt cells potentially within vacuoles as evident by punctate staining. In FOXO3 KO colon and tumors, the amount of ST8SIA5 was diminished ([Figure 6](#fig6){ref-type="fig"}). Furthermore, as a positive control, tissues were stained for Ki67, which demonstrated an increased number of proliferative cells in FOXO3 KO colon relative to WT ([Figure 6](#fig6){ref-type="fig"}*B*), confirming our previous finding of increased proliferation in response to loss of FOXO3.[@bib15] These data demonstrate that in colon loss of FOXO3 leads to altered expression of ITGA2, ADAMTS12, and ST8SIA5 transcripts with potential roles in inflammation-mediated colon cancer progression.Figure 6**Altered expression of ITGA2, ADAMTS12, and ST8SIA5 transcripts in mouse colon and tumors.** (*A*) Altered levels of select, novel transcripts in FOXO3 KO colon and tumors was confirmed by qPCR (n = 3 per group from 2 independent experiments; \*^,\#^*P* \< .05 \*relative to WT colon, ^\#^relative to WT tumor; analysis of variance and Student-Newman-Keuls post-test). (*B*) Immunohistostainings of ITGA2, ADAMTS12, ST8SIA5, and Ki67 in colon and tumors of WT and FOXO3 KO mice. In WT and FOXO3 KO colon, *gray boxes* represent optical zoom images from the crypt base, midsection, and apical region as displayed as panels on the right. *Insets* in tumor panels (WT and FOXO3 KO) depict higher magnification of tumor and stromal sections (representative staining from colon and tumors of 3 mice from 2 independent immunohistostainings, scale bar 25 μm).

Human Inflammatory Bowel Disease and Colon Cancer Progression Are Associated With Altered Expression of Novel Integrin Subunit Alpha 2, ADAM Metallopeptidase With Thrombospondin Type 1 Motif 12, and ST8 Alpha-N-Acetyl-Neuraminide Alpha-2,8-Sialyltransferase 5 Transcripts {#sec2.5}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We examined in human IBD and colon cancer patient cohorts whether altered ITGA2, ADAMTS12, and ST8SIA5 levels might play a role in their pathobiology. Similar to mouse inflammatory tumors, in IBD tissue (GSE4183) levels of both ITGA2 and ADAMTS12 transcripts were substantially increased, whereas ST8SIA5 was reduced ([Figure 7](#fig7){ref-type="fig"}*A*). In human colon cancer (TCGA), ITGA2, ADAMTS12, and ST8SIA5 expression co-occurred with established colon cancer biomarkers (data not shown), and their combined alterations including gene amplification, mutations, and mRNA/protein dysregulation were seen in 14% of colon cancer patients ([Figure 7](#fig7){ref-type="fig"}*B*). Moreover, analysis of human colon cancer transcriptomes (TCGA) indicated ITGA2 and ADAMTS12 levels were substantially increased, whereas expression of ST8SIA5 was considerably decreased compared with normal colon ([Figure 7](#fig7){ref-type="fig"}*C*; RSEM, *P* \< .001). This trend of ITGA2, ADAMTS12, and ST8SIA5 expression was also found in other cancers such as esophagus, stomach, liver, lung, kidney, breast, and prostate (data not shown). Moreover, expression levels of these transcripts in human colon as shown by RNAseq (RSEM, [Figure 7](#fig7){ref-type="fig"}*C*) appear to be similar to levels observed in mouse tissues ([Figure 6](#fig6){ref-type="fig"}*B*), eg, high ITGA2, moderate ADAMTS12, and low ST8SIA5 expression. Ultimately, in human colon cancer, increased ITGA2 and ADAMTS12 as well as decreased ST8SIA5 were associated with poor patient survival ([Figure 7](#fig7){ref-type="fig"}*D*). These data indicate that these novel transcripts dependent on loss of FOXO3 have altered expression in human IBD and colon cancer possibly implicating their role in progression of both pathobiologies.Figure 7**Expression of ITGA2, ADAMTS12, and ST8SIA5 transcripts across human IBD and colon cancer.** (*A*) In human IBD tissue samples, levels of ITGA2, ADAMTS12, and ST8SIA5 were significantly altered relative to normal control (GSE4183, n = 23 patient samples, Agilent Microarray Probe ID: ITGA2 (22734_at), ADAMTS12 (226997_at), ST8SIA5 (217514_at); \**P* \< .05 compared with healthy control, Student *t* test). (*B*) OncoPrint alteration summary of ADAMTS12, ITGA2, and ST8SIA5 in human colon cancer (TCGA) ([cbioportal.org](http://cbioportal.org){#intref0060}, *P* \< .05). (*C* and *D*) mRNA expression of select, novel transcripts ITGA2, ADAMTS12, and ST8SIA5 were significantly altered in human colon cancer compared with matched control tissue (TCGA) (TIMER, \*\*\**P* \< .001 compared with normal tissue) and were associated with poor patient survival as measured by KM estimate (PROGgeneV2) (\**P* \< .05).

In Human Colon Cancer Cells Forkhead Box O3 Silencing Mediates Increased Integrin Subunit Alpha 2 Levels Leading to Increased Proliferation {#sec2.6}
-------------------------------------------------------------------------------------------------------------------------------------------

Next, we assessed whether expression of these novel transcripts occurred in colon cancer cells, was FOXO3-dependent, and had any possible role in cancer progression. Emerging studies showed that although ITGA2 and ADAMTS12 are found in fibroblasts,[@bib41], [@bib42] their expression and potential roles in colonic cells are not examined. Thus, we generated human colon cancer HCT116 cells with FOXO3-specific knockdown using shRNA (shFOXO3) under inducible doxycycline (dox)-inducible promoter. Among several stable transfected clones, we selected those that after dox-treatment showed reduction in endogenous FOXO3 (mRNA and protein) levels (50% ± 4%) ([Figure 8](#fig8){ref-type="fig"}*A* and *C*). In HCT116 cells, with or without shFOXO3, levels of ADAMTS12 and ST8SIA5 were insignificant, as assessed by qPCR and immunoblot (data not shown), most likely because of low baseline expression (ST8SIA5) or high methylation status (ADAMTS12)[@bib41] of these genes in colon cancer cells. However, ITGA2, expressed in colon cancer HCT116 cells, was increased more than 2.5-fold in response to 50% FOXO3 knockdown ([Figure 8](#fig8){ref-type="fig"}*B* and *C*). Moreover, in human colon cancer HCT116 cells silencing of ITGA2 (siRNA) led to significant reduction in cell proliferation (47% ± 2%), indicating a potential role for this gene in colon cancer cell growth ([Figure 8](#fig8){ref-type="fig"}*D*). Although further study is required to determine whether increased ITGA2 expression is directly or indirectly dependent on loss of FOXO3, these findings demonstrate colon cancer cell specific ITGA2 regulation that could facilitate elevated cancer cell growth.Figure 8**In human colon cancer HCT116 cells FOXO3 silencing leads to increased ITGA2 levels that promote growth.** (*A*) Human colon cancer HCT116 clones with (dox)-inducible (2 μg/mL, 48 hours) FOXO3-specific shRNA (shFOXO3) were assessed for reduced FOXO3 mRNA levels (n = 4 from 2 independent experiments and clones; \*^,\#^*P* \< .05, \*compared with control (shCon) (-dox), ^\#^compared with shFOXO3 (-dox); analysis of variance and Student-Newman-Keuls post-test). (*B*) Increased ITGA2 expression in response to FOXO3 knockdown (shFOXO3) in colon cancer cells was determined by qPCR (n = 4 from 2 independent experiments and clones; \*^,\#^*P* \< .05, \*compared with shCon (-dox), ^\#^compared with shFOXO3 (-dox); analysis of variance and Student-Newman-Keuls post-test). (*C*) Immunoblot of elevated ITGA2 and reduced FOXO3 protein levels in shFOXO3 colon cancer cells (n = 4 from 2 independent experiments and clones; \*^,\#^*P* \< .05, \*compared with shCon (-dox), ^\#^compared with shFOXO3 (-dox); analysis of variance and Student-Newman-Keuls post-test). (*D*) MTS proliferation assay of colon cancer cells left untreated (control, Con) or transfected with non-specific scramble (NS) siRNA or ITGA2 specific siRNA (n = 8 per condition from 2 independent experiments; \*^,\#^*P* \< .05, \*compared with Con, ^\#^compared with NS Con; analysis of variance and Student-Newman-Keuls post-test).

Discussion {#sec3}
==========

Colon cancer increased risk, progression, and resistance to chemotherapy is linked to an inflammatory microenvironment[@bib1], [@bib3], [@bib6]; however, the mechanisms involved in inflammation promoted tumor growth are not fully understood. Here, in a mouse model of inflammation-mediated colon cancer, we identified alterations driven by loss of FOXO3 within the immune cell landscape, molecular pathways, and transcripts leading to tumor growth. In mouse colon and tumors, we validated differential expression of novel transcripts including ITGA2, ADAMTS12, and ST8SIA5 in response to FOXO3 deficiency. Their expression was similarly altered in human IBD and cancer tissues and associated with poor survival in colon cancer patients. Also, in human colon cancer cells, increased ITGA2 expression, mediated by loss of FOXO3 function, was important for cell growth. These findings provide an opportunity to pursue new mechanisms, biomarkers, and prospective targets for treatment of inflammation-mediated colon cancer.

In mouse colon, deficiency in FOXO3 led to increased tumor incidence and size in the AOM/DSS model. Similar to human inflammatory colon cancer samples,[@bib32] mouse colon deficient in FOXO3 exhibited a strong presence of neutrophils, macrophages, B and T cells, and decreased NK cells. Also, FOXO3-deficient colon and tumors had notably elevated B cells relative to WT. We speculate this effect could be a direct consequence of FOXO3 deficiency in B cells leading to their proliferation and enhanced activity[@bib10] or occurring as a result of a B-cell response to commensal bacteria because FOXO3 deficiency also activated bacterial TLR signaling. Whether this immune profile is active or inactive and possesses pro- or anti-tumor functions remains unclear; however, emerging findings in human and mouse models have revealed that individually macrophages, neutrophils, T cells, and NK cells play important roles in colon cancer progression.[@bib3], [@bib32] For example, Jobin et al[@bib43] demonstrated that individuals with lower NK cell activity in blood have substantially higher risk of developing colon cancer. Also, in mouse colon, macrophages polarized by commensal bacteria have been shown to stimulate inflammation and cancer progression.[@bib44] It has also been demonstrated that depletion of neutrophils with Ly6G antibodies ameliorates tumor number and size,[@bib45] and together, molecular crosstalk between macrophages and neutrophils could promote infiltration of T cells.[@bib46] In addition to approved immunotherapy for MSI colon cancer that stimulates T-cell anti-tumor function,[@bib47] we speculate that determining the tumor functional roles of the FOXO3-dependent immune profile could lead to its targeting for more effective immunotherapeutic treatment regimens.

Functional deficiency of FOXO3 in mouse colon led to pathway activation associated with inflammatory NFκB and tumorigenic cMyc transcriptional programs as well as bacterial TLR signaling. Although activity of these transcription factors is linked to FOXO3 function,[@bib11], [@bib14], [@bib48] the contribution of NFκB and cMyc in individual cell types in inflammation-mediated colon cancer needs to be further examined. We found increased levels of transcripts associated with inflammation and cancer, which might be directly regulated by FOXO3 or indirectly by NFκB and cMyc. Moreover, in FOXO3 KO colon, increased TLRs (level and activity) could lead to enhanced sensitivity to luminal commensal bacteria. Because bacterial products stimulate inflammation in part through loss of FOXO3 function,[@bib12], [@bib18] our findings suggest a possible feedback between FOXO3 function and TLR signaling that may also drive inflammatory tumor growth. Together, loss of colonic FOXO3 might simultaneously orchestrate downstream signaling that could promote increased sensitivity to commensal bacteria and inflammation leading to cancer initiation and progression.

We identified in mouse colon a substantial number of novel transcripts that might be directly or indirectly altered because of FOXO3 functional deficiency or consequently because of activated inflammatory-tumorigenic programs including ITGA2, ADAMTS12, and ST8SIA5. In human colon cancer tissues, increased ADAMTS12 expression is found predominantly in fibroblasts,[@bib41] and although in various human colon cancer cell lines there is lack of ADAMS12 expression because of methylation, its expression is recovered after co-culture with fibroblasts.[@bib41] Our findings demonstrate that ADAMTS12 levels, while negligibly present in human colon cancer cells, were significantly increased (transcripts and protein) in mouse colonic cells of FOXO3 KO colon and tumors, as well as in infiltrated non-colonic cells. Furthermore, in mouse colon, ST8SIA5 protein appears to localize in select colonic cells. Although in human colon cancer cells ST8SIA5 expression level was negligible, its further decrease in human colon cancer appeared to be critical for poor patient survival. Moreover, emerging findings have revealed in IBD patients that genome-wide variants in ST8SIA5 are associated with response to select therapy[@bib49]; in addition, an ST8SIA5 family member (ST8SIA1) has been recently used in immunotherapeutic vaccine delivery to stimulate NK cell activity against tumor growth.[@bib50] Thus, although ST8SIA5 levels might be low in colon, recovery of its levels/function might have potential therapeutic benefits in IBD and colon cancer. Moreover, ITGA2 abundance was found not only in mouse colonic cells and tumors but also in human colon cancer cells and was critical for cell growth. Increased ITGA2 has recently been implicated in fibroblast-driven inflammatory rheumatoid arthritis,[@bib42] resistance of gastric cancer cells to apoptosis,[@bib51] and human colon cancer metastasis.[@bib52] We speculate that in colon elevated ITGA2 exerts multiple functions in colonic and non-colonic cells to facilitate inflammation-mediated cancer pathobiology. Moreover, because we found that partial reduction in FOXO3 levels in human colon cancer cells led to significantly increased ITGA2 expression, we speculate that in human colon SNPs in the FOXO3 gene might have significant implications in driving gene expression involved in inflammatory and cancer progression. In addition, whether these novel transcripts are directly or indirectly regulated by FOXO3 is unclear; they could act as novel functional regulators in inflammation-mediated colon cancer progression.

In conclusion, FOXO3 deficiency in a mouse model of inflammation-mediated colon cancer increases colonic tumor burden. Moreover, loss of FOXO3 also leads to elevated intracellular lipids,[@bib53] an emerging aspect of metabolic reprogramming associated with inflammation and colon cancer,[@bib54] suggesting FOXO3's metabolic function may also be involved in these disease processes. These findings underline novel FOXO3-dependent regulators that could serve as biomarkers and prospective new targets for treatment of colon cancer. Overall, understanding the immune landscape and molecular pathways of inflammation-mediated colon cancer highlights a future direction for precision diagnostics and personalized treatments.
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[^1]: Indicates colon cancer biomarker (FDR \< 0.05, fold change \>\|1.5\|, IPA.
